A Phase II Exploratory Study of Pre-Operative Treatment with Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy.

Trial Profile

A Phase II Exploratory Study of Pre-Operative Treatment with Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2018.
    • 26 Apr 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016, as reported by ClinicalTrials.gov.
    • 24 Apr 2014 Planned End Date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top